Search
Novartis' Riociguat Receives Approval in China for IgA Nephropathy Treatment
2025-08-20 /
Read about 0 minute
Author：小编
Novartis has announced that its groundbreaking product, Riociguat® (Atacurium Hydrochloride Tablets), has secured approval from the National Medical Products Administration for use in reducing proteinuria in adult patients with primary IgA nephropathy who are at risk of rapid disease progression. This approval marks Riociguat as the first non-immunological therapy in China specifically indicated for the treatment of IgA nephropathy. Additionally, it stands as the first and only highly selective endothelin A (ETA) receptor antagonist available in China for this purpose.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
